


ATP

Adenosine 5'-triphosphate, 100 mM sodium salt solution

	Cat. No.	Volume	Concentration
	ATP_100ML	100 ml	100 mM
	ATP_1000ML	1000 ml	100 mM



Structural formula of ATP – Solution

For *in vitro* use only!

Shipping: shipped on blue ice

Storage Conditions: store at -20 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible. If stored as recommended, Jena Bioscience guarantees optimal performance of this product for 12 months after date of delivery.

Shelf Life: 12 months

Molecular Formula: C₁₀H₁₃N₅O₁₃P₃ (Anion)

Molecular Weight: 504.16 g/mol (Anion)

CAS#: 987-65-5

Purity: > 99 % (HPLC)

Form: clear aqueous solution

Concentration: 100 mM ± 2 %

pH: 8.0 ± 0.2 (22 °C)

Spectroscopic Properties: λ_{max} 259 nm; ε 15.1 L mmol⁻¹ cm⁻¹ (pH 7.0)

Applications:

ATP-sensitive calcium channels^[1]
V-ATPases (cellular proton pumps)^[2]
ATP-coupled chromatin remodelling^[3]
ATP-binding cassette transporters^[4]
ATP-grasp enzymes^[5]
Agonistic ligand, mainly for nucleoside receptor A₁
Nucleoside-triphosphates can be converted by different membrane-bound phosphatases into nucleosides acting as nucleoside receptor ligands.

Description:

Ultrapure ATP supplied as clear aqueous solution.

Specific Ligands:

Ligand for purinergic receptors:

P2X₁-P2X₃^[6,7]

P2X_{1/4}^[8]

P2X₄^[7]

P2X₇^[9,10,11]

P2X₁ - P2X₇^[12]

P2Y₁^[10,14]

P2Y₂^[13,14]

P2Y₁₁^[14]

Selected References:

[1] Wang *et al.* (2011) The biological effect of endogenous sulfur dioxide in the cardiovascular system. *Eur. J. Pharmacol.* **670** (1):1

[2] Scott *et al.* (2011) Duelling functions of the V-ATPase. *EMBO J.* **30** (20):4113.

[3] Erdel *et al.* (2011) Chromatin remodelling in mammalian cells by ISWI-type complexes--where, when and why? *FEBS J.* **278** (19):3608.

[4] Gatti *et al.* (2011) Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. *Curr. Med. Chem.* **18** (27):4237.

ATP

Adenosine 5'-triphosphate, 100 mM sodium salt solution



[5] Fawaz *et al.* (2011) The ATP-grasp enzymes. *Bioorg. Chem.* **39** (5):185.

[6] Lambertucci *et al.* (2015) Medicinal chemistry of P2X receptors: Agonists and orthosteric antagonists. *Curr. Med. Chem.* **22** (7):915.

[7] Ralevic (2015) P2X receptors in the cardiovascular system and their potential as therapeutic targets in disease. *Curr. Med. Chem.* **22** (7):851.

[8] Harhun *et al.* (2014) ATP-evoked sustained vasoconstrictions mediated by heteromeric P2X1/4 receptors in cerebral arteries. *Stroke* **45** (8):2444.

[9] Facci *et al.* (2014) Toll-like receptors 2, -3 and -4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1 β release. *Sci. Rep.* **4**:6824.

[10] Stolz *et al.* (2015) Homodimeric anoctamin-1, but not homodimeric anoctamin-6, is activated by calcium increases mediated by the P2Y1 and P2X7 receptors. *Pflugers Archiv* DOI:10.1007/s00424-015-1687-3.

[11] Lord *et al.* (2014) Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. *J. Pharmacol. Exp. Ther.* **351** (3):628.

[12] Dal Ben *et al.* (2015) Purinergic P2X receptors: Structural models and analysis of ligand-target interaction. *Eur. J. Med. Chem.* **89**:561.

[13] Xie *et al.* (2014) The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. *J. Biol. Chem.* **289** (27):19137.

[14] Kim *et al.* (2002) Methanocarpa modification of uracil and adenine nucleotides: High potency of northern ring conformation at P2Y1, P2Y2, P2Y4 and P2Y11 but not P2Y6 receptors. *J. Med. Chem.* **45**:208.

Volonte *et al.* (2009) Membrane components and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. *FEBS J.* **276**:318.

Yegutkin (2008) Nucleotide and nucleoside converting enzymes: Important modulators of purinergic signalling cascade. *Biochim. Biophys. Acta* **1783**:673.

Hasko *et al.* (2007) Shaping of monocyte and macrophage function by adenosine receptors. *Pharmacol. &*

Therapeutics **113**:264.

Holland *et al.* (1991) Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of *Thermus aquaticus* DNA polymerase. *Proc. Natl. Acad. Sci. USA* **88** (16):7276.

Erlich *et al.* (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* **29** (239):487.

Williams *et al.* (1986) Effects of purine nucleotides on the binding of [3H]cyclopentyladenosine to adenosine A1-receptors in rat brain membranes. *J. Neurochem.* **47** (1):88.

Sanger *et al.* (1977) DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**:5463.